Robert Harrington to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Robert Harrington has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.835
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
Score: 0.174
-
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 11 21; 41(44):4245-4255.
Score: 0.155
-
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 09 03; 74(9):1177-1186.
Score: 0.143
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
Score: 0.100
-
Clinical decisions. Management of stable coronary disease. N Engl J Med. 2007 Oct 25; 357(17):1762-6.
Score: 0.063
-
Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.
Score: 0.057
-
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c
View in: PubMed
Score: 0.037
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES. J Am Coll Cardiol. 2020 02 04; 75(4):448-451.
Score: 0.037
Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 07 09; 140(2):103-112.
Score: 0.035
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 02 05; 73(4):387-396.
Score: 0.034